Drug guidance
Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
Condition
Blood and Immune System
Cancer
17 February 2025
Published on 01 Aug 2024
Last Updated on 4 Jun 2025
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Tisagenlecleucel cells dispersion for infusion for treating patients 18 years of age and above with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Funding status
Tisagenlecleucel cells dispersion for infusion is recommended for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for the abovementioned indication from 1 August 2024.
Tisagenlecleucel should be used in line with the additional clinical criteria listed in the Annex.